Clinical Trial Update: Risk of Squamous Cell Carcinoma on Skin Areas Treated With Ingenol Mebutate Gel, 0.015% and Imiquimod Cream, 5% [Phase 4]

View source ↗

Summary

Phase 4 trial update on the risk of squamous cell carcinoma at skin sites treated with Ingenol Mebutate Gel 0.015% and Imiquimod Cream 5% in actinic keratosis; …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Actinic Keratosis
• Squamous Cell Carcinoma of the Skin

Drugs mentioned

• Imiquimod Cream 5% (imiquimod)
• Ingenol Mebutate Gel, 0.015% (ingenol mebutate)

Snippet

Sponsor: LEO Pharma | Conditions: Actinic Keratosis (AK) | Phase 4 | Status: COMPLETED | Results posted: 2020-07-29